SEARCH

SEARCH BY CITATION

References

  • 1
    Bos JL,Fearon ER,Hamilton SR,Verlaan-de Vries M,van Boom JH,van der Eb AJ,Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 2937.
  • 2
    Almoguera C,Shibata D,Forrester K,Martin J,Arnheim N,Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 54954.
  • 3
    Hruban RH,van Mansfeld AD,Offerhaus GJ,van Weering DH,Allison DC,Goodman SN,Kensler TW,Bose KK,Cameron JL,Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 54554.
  • 4
    Lemoine NR,Mayall ES,Wyllie FS,Williams ED,Goyns M,Stringer B,Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4: 15964.
  • 5
    Schutte M,Kern SE. The molecular genetics of pancreatic adenocarcinoma. In: NeoptolemosJP,LemoineNR. eds. Pancreatic cancer. Oxford: Blackwell Scientific Publications, 1996; 11532.
  • 6
    Wynford-Thomas D. Molecular genetics of thyroid cancer. Curr Opin Endocrinol Diab 1995; 2: 42936.
  • 7
    Bond JA,Wyllie FS,Rowson J,Radulescu A,Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994; 9: 28190.
  • 8
    Jones CJ,Kipling D,Morris M,Hepburn P,Skinner J,Bounacer A,Wyllie FS,Ivan M,Bartek J,Wynford-Thomas D,Bond JA. Evidence for a telomere-independent “clock”; limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol 2000; 20: 569099.
  • 9
    Blumberg M. Complexities of the protein kinase C pathway. Mol Carcinogen 1991; 4: 33944.
  • 10
    Bond J,Dawson T,Lemoine NR,Wynford-Thomas D. Effect of serum growth factors and phorbol ester on growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinogen 1992; 5: 12935.
  • 11
    Dawson T,Bond J,Eccles N,Wynford-Thomas D. Toxicity of phorbol esters for human epithelial cells expressing a mutant ras oncogene. Mol Carcinogen 1993; 8: 2809.
  • 12
    Hall-Jackson C,Jones T,Eccles N,Dawson T,Bond J,Gescher A,Wynford-Thomas D. Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. Br J Cancer 1998; 78: 64151.
  • 13
    Parker PJ,Bosca L,Dekker L,Goode NT,Hajibagheri N,Hansra G. Protein kinase C (PKC)-induced PKC degradation: a model for down- regulation. Biochem Soc Trans 1995; 23: 1535.
  • 14
    Droms KA,Malkinson AM. Phorbol ester-induced tumor promotion by downregulation of protein kinase C. Mol Carcinogen 1991; 4: 12.
  • 15
    Geer RJ,Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 6872.
  • 16
    Thorpe WP,Toner M,Ezzell RM,Tompkins RG,Yarmush ML. Dynamics of photoinduced cell plasma membrane injury. Biophys J 1995; 68: 2198206.
  • 17
    Smith PJ,Blunt N,Wiltshire M,Hoy T,Teesdale-Spittle P,Craven MR,Watson JV,Amos WB,Errington RJ,Patterson LH. Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopy. Cytometry 2000; 40: 28091.
  • 18
    Bond J,Haughton M,Rowson J,Gire V,Wynford-Thomas D,Wyllie F. Control of replicative lifespan in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol 1999; 19: 310314.
  • 19
    Marshman E,Ottewell PD,Potten CS,Watson AJ. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol 2001; 195: 28592.
  • 20
    Moore PS,Sipos B,Orlandini S,Sorio C,Real FX,Lemoine NR,Gress T,Bassi C,Klöppel G,Kalthoff H,Ungefroren H,Löhr M, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439: 798802.
  • 21
    Sirivatanauksorn V,Sirivatanauksorn Y,Gorman PA,Davidson JM,Sheer D,Moore PS,Scarpa A,Edwards PAW,Lemoine NR. Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. Int J Cancer 2001; 91: 3508.
  • 22
    Wang QJ,Fang TW,Fenick D,Fenick D,Garfield S,Bienfait B,Marquez VE,Blumberg PM. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J Biol Chem 2000; 275: 1213646.
  • 23
    Stone RM,Sariban E,Pettit GR,Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72: 20813.
  • 24
    Propper DJ,Macaulay V,O'Byrne KJ,Braybrooke JP,Wilner SM,Ganesan TS,Talbot DC,Harris AL. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998; 78: 133741.
  • 25
    Varterasian ML,Mohammad RM,Shurafa MS,Hulburd K,Pemberton PA,Rodriquez DH,Spadoni V,Eilender DS,Murgo A,Wall N,Dan M,Al-Katib AM. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6: 8258.
  • 26
    Stanwell C,Gescher A,Bradshaw TD,Pettit GR. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer 1994; 56: 58592.
  • 27
    Graff JM,Young TN,Johnson JD,Blackshear PJ. Phosphorylation-regulated calmodulin binding to a prominent substrate for protein kinase C. J Biol Chem 1989; 264: 2181823.
  • 28
    Barry OP,Kazanietz MG. Protein kinase c isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001; 7: 172544.
  • 29
    Day ML,Zhao X,Wu S,Swanson PE,Humphrey PA. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 1994; 5: 73541.
  • 30
    Zheng X,Chang RL,Cui X-X,Avila GE,Lee S,Lu YP,Lou YR,Shih WJ,Lin Y,Reuhl K,Newmark H,Rabson AB, et al. Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumours in immunodeficient mice. Cancer Res 2004; 64: 181120.
  • 31
    Park IC,Park MJ,Rhee CH,Lee JI,Choe TB,Jang JJ,Lee SH,Hong SI. Protein kinase C activation by PMA rapidly induces apoptosis through caspase-3/CPP32 and serine protease(s) in a gastric cancer cell line. Int J Oncol 2001; 18: 107783.
  • 32
    Avila GE,Zheng X,Cui XX,Ryan AD,Hansson A,Suh J,Rabson AB,Chang RL,Shih WJ,Lin Y,Crowell P,Lu YP, et al. Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice. J Pharmacol Exp Ther 2005; 315: 17087.
  • 33
    Powell CT,Yin L. Overexpression of PKCΣ sensitizes LNCaP human prostate cells to induction of apoptosis by bryostatin 1. Int J Cancer 2006; 118: 15726.
  • 34
    Engedal N,Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 2001; 46: 28997.
  • 35
    Detjen KM,Brembeck FH,Welzel M,Kaiser A,Haller H,Weidenmann B,Rosewicz S. Activation of protein kinase C alpha inhibits growth of pancreatic cancer cells via p 21(cip)-mediated G1 arrest. J Cell Sci 2000; 113: 302535.
  • 36
    Kazanietz MG,Caloca MJ,Eroles P,Fujii T,Garcia-Bermejo ML,Reilly M,Wang H. Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties. Biochem Pharmacol 2000; 60: 141724.
  • 37
    Kazanietz MG. Targeting protein kinase C and “non-kinase” phorbol ester receptors: emerging concepts and therapeutic implications. Biochim Biophys Acta 2005; 1754: 296304.
  • 38
    Tognon CE,Kirk HE,Passmore LA,Whitehead IP,Der CJ,Kay RJ. Regulation of Ras GRP via a phorbol ester-responsive C1 domain. Mol Cell Biol 1998; 18: 69957008.
  • 39
    Caloca MJ,Fernandez N,Lewin NE,Ching D,Modali R,Blumberg PM,Kazanietz MG. Beta 2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J Biol Chem 1997; 272: 2648896.
  • 40
    Brose N,Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 2002; 115: 4399411.
  • 41
    Song Y,Ailenberg M,Silverman M. Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Mol Biol Cell 1999; 10: 160919.
  • 42
    Hamada K,Nakamura H,Oda T,Hirano T,Shimizu N,Utiyama H. Involvement of Mac-1-mediated adherence and sphingosine 1-phosphate in survival of phorbol ester-treated U937 cells. Biochem Biophys Res Commun 1998; 244: 74550.
  • 43
    Rosfjord EC,Maemura M,Johnson MD,Torri JA,Akiyama SK,Woods VL,Jr,Dickson RB. Activation of protein kinase C by phorbol esters modulates alpha 2beta 1 integrin on MCF-7 breast cancer cells. Exp Cell Res 1999; 248: 26071.
  • 44
    Strair RK,Schaar D,Goodell L,Aisner J,Chin KV,Eid J,Senzan R,Cui XX,Han ZT,Knox B,Rabson AB,Chang R, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002; 8: 251218.
  • 45
    Han ZT,Tong YK,He LM,Zhang Y,Sun JZ,Wang TY,Zhang H,Cui YL,Newmark HL,Conney AH,Chang RL. 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad of Sci USA 1998a; 95: 53625.
  • 46
    Han ZT,Zhu XX,Yang RY,Sun JZ,Tian GF,Liu XJ,Cao GS,Newmark HL,Conney AH,Chang RL. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad of Sci USA 1998b; 95: 535761.
  • 47
    Cui XX,Chang RL,Zheng X,Woodward D,Strair R,Conney AH. A sensitive bioassay for measuring blood levels of 12-O-Tetradecanoylphorbol-13-acetate(TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 2002; 13: 16974.
  • 48
    Schaar D,Goodell L,Aisner J,Cui XX,Han ZT,Chang R,Martin J,Grospe S,Dudek L,Riley J,Manago J,Lin Y, et al. A phase 1 clinical trial of 12 O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 2006; 57: 78995.